Patel Jeegar Pravinkumar 4
4 · Evommune, Inc. · Filed Apr 17, 2026
Research Summary
AI-generated summary of this filing
Evommune (EVMN) CSO Jeegar Patel Receives 69,315-Share Award
What Happened
Jeegar Pravinkumar Patel, Chief Scientific Officer of Evommune, was granted a derivative award of 69,315 shares on 2026-04-16. The filing lists the grant price as $0.00 and treats the award as a derivative (an option award per the footnote), so no cash was exchanged at grant.
Key Details
- Transaction date: 2026-04-16; Form 4 filed: 2026-04-17 (timely filing).
- Transaction type/code: A — Grant/award (derivative).
- Shares/units: 69,315 shares; price shown: $0.00.
- Vesting: One‑fourth vests on the first anniversary of the grant, then the remainder vests in 36 equal monthly installments thereafter (continuous service required).
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Footnote: Filing identifies this as an option award with the vesting schedule described above.
Context
This is a compensation-related derivative grant rather than an open‑market purchase or sale. Such awards are common for executives and are designed to align long‑term incentives; they do not by themselves indicate the insider bought or sold stock for investment purposes. The award will convert to exercisable/vested equity over time per the vesting schedule.
Insider Transaction Report
- Award
Employee Stock Option (Right to Buy)
[F1]2026-04-16+69,315→ 69,315 totalExercise: $26.77Exp: 2036-04-15→ Common Stock (69,315 underlying)
Footnotes (1)
- [F1]One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.